Assetmark Inc. Purchases 1,036 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Assetmark Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,316 shares of the biopharmaceutical company’s stock after purchasing an additional 1,036 shares during the period. Assetmark Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,516,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. PeakShares LLC lifted its position in shares of Regeneron Pharmaceuticals by 1.5% during the 1st quarter. PeakShares LLC now owns 1,450 shares of the biopharmaceutical company’s stock worth $1,120,000 after buying an additional 22 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Regeneron Pharmaceuticals by 39.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 52,497 shares of the biopharmaceutical company’s stock worth $40,803,000 after acquiring an additional 14,938 shares in the last quarter. Independent Financial Group LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth about $782,000. Prosperity Consulting Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the first quarter. Prosperity Consulting Group LLC now owns 360 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 20 shares during the last quarter. Finally, Aware Super Pty Ltd as trustee of Aware Super bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $2,938,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Canaccord Genuity Group decreased their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $787.67.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title
• Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title
• Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ REGN opened at $672.15 on Tuesday. The company has a 50 day simple moving average of $640.18 and a 200 day simple moving average of $717.26. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The firm has a market cap of $71.06 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the previous year, the firm posted $8.22 EPS. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.